Colorectal liver metastases
Conditions
Brief summary
Overall Survival (OS)
Detailed description
Progression-free Survival (PFS), Hepatic Progression-free Survival (hPFS), Conversion to resection rate, Objective response rate (ORR), Disease Control Rate (DCR), Pathological response rate, Surgical complication rate (Clavien Dindo classification), Adverse events and toxicity ≥ 3 (according to Common Terminology Criteria for Adverse Events (CTCAE), version 5.0), Quality of Life (QoL), Costs per quality adjusted life years (QALYs)
Interventions
DRUGIRINOTECAN
DRUGHEPARIN
DRUGOXALIPLATIN
DRUGCAPECITABINE
DRUGBEVACIZUMAB
DRUGFLUOROURACIL
DRUGCALCIUM FOLINATE
DRUGDEXAMETHASONE
Sponsors
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Survival (OS) | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free Survival (PFS), Hepatic Progression-free Survival (hPFS), Conversion to resection rate, Objective response rate (ORR), Disease Control Rate (DCR), Pathological response rate, Surgical complication rate (Clavien Dindo classification), Adverse events and toxicity ≥ 3 (according to Common Terminology Criteria for Adverse Events (CTCAE), version 5.0), Quality of Life (QoL), Costs per quality adjusted life years (QALYs) | — |
Countries
Netherlands
Outcome results
None listed